Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

2 maja 2017 zaktualizowane przez: Teva Branded Pharmaceutical Products R&D, Inc.

A 12-Month, Open-Label Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours in Patients Who Require Opioid Treatment for an Extended Period of Time

The primary objective of this study is to evaluate the safety of hydrocodone extended-release tablets when used over a 12-month period in patients with chronic pain, as assessed by adverse events, clinical laboratory results, vital signs measurements, electrocardiogram results, physical examination findings, pure tone audiometry, and concomitant medication usage.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

This was a Phase 3, open-label, nonrandomized study that consisted of a screening period, an open label titration period, and a 52 week, long term, open-label treatment period in patients with chronic pain. Patients were eligible to participate in this study if they had completed study C33237/3079 (NCT01240863) (these patients are hereafter referred to as rollover patients) or if they had not participated in study 3079 (these patients are hereafter referred to as either new opioid naïve or new opioid experienced patients).

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

330

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Stany Zjednoczone
    • Alabama
      • Mobile, Alabama, Stany Zjednoczone
        • Horizon Research Group, LLC
    • California
      • Anaheim, California, Stany Zjednoczone
        • Physician Alliance Research Center
      • Beverly Hills, California, Stany Zjednoczone
        • Adam D. Karns, MD
      • Buena Park, California, Stany Zjednoczone
        • Associated Pharmaceutical Research Center, Inc.
      • Burbank, California, Stany Zjednoczone
        • Providence Clinical Research
      • Fresno, California, Stany Zjednoczone
        • Research Center of Fresno, Inc.
      • Laguna Hills, California, Stany Zjednoczone
        • Pacific Coast Pain Management Center
      • Laguna Hills, California, Stany Zjednoczone
        • South Orange County Surgical Medical Group
      • San Diego, California, Stany Zjednoczone
        • Accelovance, Inc.
      • Valley Village, California, Stany Zjednoczone
        • Bayview Research Group, LLC
    • Florida
      • Clearwater, Florida, Stany Zjednoczone
        • Clinical Research of West Florida, Inc.
      • DeLand, Florida, Stany Zjednoczone
        • Avail Clinical Research, LLC
      • Orlando, Florida, Stany Zjednoczone
        • Compass Research, LLC
      • Sarasota, Florida, Stany Zjednoczone
        • Sarasota Pain Medicine Research LLC
      • Weston, Florida, Stany Zjednoczone
        • Gold Coast Research LLC
    • Georgia
      • Marietta, Georgia, Stany Zjednoczone
        • Drug Studies America
      • Marietta, Georgia, Stany Zjednoczone
        • Georgia Institute for Clinical Research, LLC
      • Marietta, Georgia, Stany Zjednoczone
        • Taylor Research, LLC
      • Newnan, Georgia, Stany Zjednoczone
        • Better Health Clinical Research, Inc.
    • Illinois
      • Bloomington, Illinois, Stany Zjednoczone
        • Millennium Pain Center
    • Indiana
      • Indianapolis, Indiana, Stany Zjednoczone
        • Rehabilitation Associates of Indiana
    • Kansas
      • Overland Park, Kansas, Stany Zjednoczone
        • International Clinical Research, Inc.
    • Kentucky
      • Crestview Hills, Kentucky, Stany Zjednoczone
        • Community Research
    • Louisiana
      • Shreveport, Louisiana, Stany Zjednoczone
        • Willis Knighton River Cities Clinical Research Center
    • Maryland
      • Pikesville, Maryland, Stany Zjednoczone
        • MidAtlantic Pain Medicine Center
    • Massachusetts
      • Brockton, Massachusetts, Stany Zjednoczone
        • Beacon Clinical Research, LLC
    • Missouri
      • Florissant, Missouri, Stany Zjednoczone
        • HealthCare Research
      • Saint Louis, Missouri, Stany Zjednoczone
        • Sundance Clinical Research, LLC
    • Nebraska
      • Omaha, Nebraska, Stany Zjednoczone
        • Meridian Clinical Research
    • Nevada
      • Las Vegas, Nevada, Stany Zjednoczone
        • Clinical Research Center of Nevada
    • New Jersey
      • Voorhees, New Jersey, Stany Zjednoczone
        • Advanced Pain Consultants
    • New York
      • Williamsville, New York, Stany Zjednoczone
        • Upstate Clinical Research Associates
    • North Carolina
      • Raleigh, North Carolina, Stany Zjednoczone
        • Wake Research Associates
    • Ohio
      • Cincinnati, Ohio, Stany Zjednoczone
        • Sterling Research Group, Ltd.
      • Columbus, Ohio, Stany Zjednoczone
        • Columbus Clinical Research
    • Oklahoma
      • Oklahoma City, Oklahoma, Stany Zjednoczone
        • SP Research
    • Oregon
      • Eugene, Oregon, Stany Zjednoczone
        • Pain Research of Oregon
      • Portland, Oregon, Stany Zjednoczone
        • Summit Research Network Inc.
    • Pennsylvania
      • Downingtown, Pennsylvania, Stany Zjednoczone
        • Brandywine Clinical Research
      • Feasterville-Trevose, Pennsylvania, Stany Zjednoczone
        • AMH Feasterville Family Health Care Center
      • Tipton, Pennsylvania, Stany Zjednoczone
        • Tipton Medical and Diagnostic Center
      • West Reading, Pennsylvania, Stany Zjednoczone
        • Clinical Research Center of Reading, LLP
    • Rhode Island
      • Warwick, Rhode Island, Stany Zjednoczone
        • Omega Medical Research
    • South Carolina
      • Greenville, South Carolina, Stany Zjednoczone
        • Greenville Pharmaceutical Research
      • North Charleston, South Carolina, Stany Zjednoczone
        • Trident Institute of Medical Research, LLC
      • Spartanburg, South Carolina, Stany Zjednoczone
        • S. Carolina Pharmaceutical Research
    • Texas
      • Dallas, Texas, Stany Zjednoczone
        • KRK Medical Research
      • Dallas, Texas, Stany Zjednoczone
        • Radiant Research
      • Dallas, Texas, Stany Zjednoczone
        • Renaissance Clinical Research & Hypertension of Texas, PLLC
      • Houston, Texas, Stany Zjednoczone
        • MedStar Clinical Research
      • San Angelo, Texas, Stany Zjednoczone
        • Benchmark Research
      • Sugar Land, Texas, Stany Zjednoczone
        • DCT-Sugarland, LLC dba Discovery Clinical Trials
      • Waco, Texas, Stany Zjednoczone
        • Hillcrest Family Health Centers
    • Utah
      • Orem, Utah, Stany Zjednoczone
        • Aspen Clinical Research, LLC

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 80 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • The patient must be willing and able to successfully self-administer the study drug, comply with study restrictions, and return to the clinic for scheduled study visits as specified in this protocol.
  • The patient has either completed Cephalon study 3079 or has chronic pain of at least 3 months duration prior to entering this study associated with any of the following conditions: diabetic peripheral neuropathy, postherpetic neuralgia, traumatic injury, complex regional pain syndrome, back pain, neck pain, osteoarthritis, or rheumatoid arthritis. Patients with other painful conditions may qualify for the study with permission from the Cephalon medical monitor or designee.
  • Those patients who completed the 12-week, double-blind, placebo-controlled, randomized study (study 3079) and are willing to re-titrate study drug to an effective dose of hydrocodone extended-release tablets are eligible to enter this study.
  • The patient is able to speak English, willing to provide written informed consent, and sign a written opioid agreement, to participate in this study.
  • The patient is 18 through 80 years of age (inclusive) at the time of entering this or the previous study (study 3079).
  • Women of childbearing potential (not surgically sterile or 2 years postmenopausal), must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study, and have a negative pregnancy test at screening.

Exclusion Criteria:

  • Patients who were enrolled in study 3079 but did not complete the 12-week, double-blind, placebo-controlled, randomized study may not be enrolled into this study.
  • The patient has known or suspected hypersensitivities, allergies, or other contraindications to the study drug or its excipients.
  • The patient has a recent history (within 5 years) or current evidence of alcohol or other substance abuse.
  • The patient has a medical or psychiatric condition/disease that, in the opinion of the investigator, would compromise collected data.
  • The patient is taking a total (i.e., including around-the clock [ATC] and rescue medications) of more than 135 mg/day of oxycodone or equivalent for 14 days prior to screening.
  • The patient has a history of suicidality.
  • The patient has a diagnosis of chronic headache or migraine as the primary painful condition under study.
  • The patient is expected to have surgery during the study and it is anticipated that the surgery will alleviate the patient's pain.
  • The patient is pregnant or lactating.
  • The patient has active malignancy.
  • The patient has human immunodeficiency virus (HIV).
  • In the judgment of the investigator, the patient has any clinically significant deviation from normal in the physical examination and/or clinical laboratory test values.
  • The patient has cardiopulmonary disease that would, in the opinion of the investigator, significantly increase the risk of treatment with potent synthetic opioids.
  • The patient has participated in a study involving an investigational drug in the previous 30 days (excluding those who participated in study 3079).
  • The patient has received a monoamine oxidase inhibitor (MAOI) within 14 days before the first treatment with study drug.
  • The patient has any other medical condition or is receiving concomitant medication/therapy (e.g., regional nerve block) that would, in the opinion of the investigator, compromise the patient's safety or compliance with the study protocol, or compromise collected data.
  • The patient is involved in active litigation in regard to the chronic pain currently being treated.
  • The patient has a positive urine drug screen (UDS) for an illicit substance or medication not prescribed by the physician currently treating the chronic pain.
  • The investigator feels that the patient is not suitable for the study.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Hydrocodone ER
Participants were titrated (or re-titrated for roll-over participants) at escalating dosages of extended-release hydrocodone tablets at dosages of 15, 30, 45, 60, or 90 mg orally every 12 hours until deemed successful for managing their pain during the open-label titration period. Once a successful dose was identified, participants entered the 52 week open-label treatment period in which hydrocodone ER was administered at the successful dose (15, 30, 45, 60, or 90 mg) every 12 hours.
Lek: Hydrocodone ER
Hydrocodone bitartrate extended-release tablets were administered at doses of 15, 30, 45, 60, and 90 mg orally every 12 hours. During the open-label titration period, doses were adjusted until a stable pain control was achieved. In general, the dose of hydrocodone extended release tablets could be adjusted for efficacy or tolerability, as necessary, at any time during the open-label treatment period; however, participants were required to visit the study center before increasing the dose of study drug.
Inne nazwy:
  • CEP-33237
  • Dwuwinian hydrokodonu o przedłużonym uwalnianiu

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Participants With Adverse Experiences
Ramy czasowe: Day 1 of open-label titration period - Week 52 of the open-label treatment period
An adverse event (AE) was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
Day 1 of open-label titration period - Week 52 of the open-label treatment period
Participants With Potentially Clinically Significant (PCS) Abnormal Laboratory Values During the Open-Label Treatment Period by Participant Status
Ramy czasowe: Day 1 - Week 52 of the open-label treatment period

Data represents participants with PCS abnormal serum chemistry, hematology and urinalysis values.

Significance criteria:

  • alanine aminotransferase (ALT): >=3 times the upper limit of normal (ULN). Normal range is 6-43 U/L
  • aspartate aminotransferase (AST): >=3 times ULN. Normal range is 9-36 U/L
  • blood urea nitrogen (BUN): >=10.71 mmol/L
  • creatinine: >=177 μmol/L
  • uric acid: M>=625, F>=506 μmol/L
  • white blood cell count: <=3.0*10^9/L
  • hemoglobin: M<=115, F<=95 g/dL
  • hematocrit: M<0.37, F<0.32 L/L
  • urine blood (hemoglobin): >=2 unit increase from baseline
  • urine glucose: >=2 unit increase from baseline
Day 1 - Week 52 of the open-label treatment period
Participants With Potentially Clinically Significant Abnormal Vital Signs Values by Participant Status
Ramy czasowe: Day 1 of open-label titration period - Week 52 of the open-label treatment period

Data represents participants with potentially clinically significant (PCS) vital sign values.

Significance criteria

  • Pulse - high: >=120 and increase of >= 15 beats/minute from baseline
  • Pulse - low: <=50 and decrease of >=15 beats/minute
  • Systolic blood pressure - high: >=180 and increase >=20 mmHg
  • Systolic blood pressure - low: <=90 and decrease >=20 mmHg
  • Diastolic blood pressure - high: >=105 and increase of >=15 mmHg
  • Diastolic blood pressure - low: <=50 and decrease of >=15 mmHg
Day 1 of open-label titration period - Week 52 of the open-label treatment period
Shifts in Electrocardiogram (ECG) Findings From Baseline to Overall Study by Participant Status
Ramy czasowe: Baseline for new participants was between Day -7 and -14 (the study 3080 screening visit); baseline for rollover participants was the last ECG in study 3079. During study ECGs were performed on weeks 24 and 52 of the open-label treatment period

A 12-lead ECG was conducted at screening, week 24, and week 52 or at the last postbaseline observation. For rollover participants, the ECG performed at the final visit of study 3079 served as the 1st ECG in study 3080. A qualified physician was responsible for interpreting the ECG. Any ECG finding that was judged by the investigator as a clinically meaningful change (worsening) compared with baseline was considered an adverse event.

For overall results, the worst postbaseline finding for the participant was summarized.

Results below are formatted as Baseline ECG result - Overall ECG result.
Baseline for new participants was between Day -7 and -14 (the study 3080 screening visit); baseline for rollover participants was the last ECG in study 3079. During study ECGs were performed on weeks 24 and 52 of the open-label treatment period
Participants With Clinically Significant (CS) Hearing Changes From Baseline in Pure Tone Audiometry Test Results by Patient Status
Ramy czasowe: Baseline for new participants was between Day -7 and -14 (study 3080 screening visit); baseline for rollover participants was the baseline test in study 3079. During study covers both open-label titration and 52-week treatment periods
Pure tone audiometry was performed by trained personnel. During the test, the patient wore headphones and was seated in a quiet room; trained personnel manipulated the audiometry equipment to test the patient's hearing. For serial audiograms, the criteria for a clinically significant (CS) hearing change were based on the guidance from the American Speech-Language Hearing Association (ASHA) 1994 (Konrad-Martin et al 2005). These criteria included the following: greater than 20 decibels (dB) pure tone threshold shift at 1 frequency; greater than 10 dB shift at 2 consecutive test frequencies; or threshold response shifting to "no response" at 3 consecutive test frequencies.
Baseline for new participants was between Day -7 and -14 (study 3080 screening visit); baseline for rollover participants was the baseline test in study 3079. During study covers both open-label titration and 52-week treatment periods

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Participant Global Assessment (PGA) of the Method of Pain Control by Participant Status
Ramy czasowe: Baseline for new participants was Day 1, i.e. the first day of open-label titration. Baseline for rollover participants was the baseline in study 3079. Week 4 (end of titration, start of open-label treatment), Week 52, last visit up to Week 52
The PGA of the method of pain control consisted of a asking patients a single question to assess their method of pain control during the previous 24 hours as either poor, fair, good, or excellent (Rothman et al 2009).
Baseline for new participants was Day 1, i.e. the first day of open-label titration. Baseline for rollover participants was the baseline in study 3079. Week 4 (end of titration, start of open-label treatment), Week 52, last visit up to Week 52
Participants by Risk Category for Aberrant Drug Misuse Based on the Total Score in the Screener and Opioid Assessment for Patients With Pain - Revised (SOAPP-R)
Ramy czasowe: End of Open-label Titration Period. Weeks 4 and 24 of the Open-label Treatment Period

SOAPP-R is a clinician-rated scale used to assess each patient's risk of developing aberrant drug use behaviors while on long term opioid therapy. SOAPP-R consists of 24 questions that address 8 concepts: substance abuse history, medication related behaviors, antisocial behaviors/history, psychosocial problems, psychiatric history, physician patient relationship factors, emotional attachment to pain medications, and personal care and lifestyle issues (Butler et al 2008). Each question is answered using a 5 point Likert-like scale, with 0=never, 1=seldom, 2=sometimes, 3=often, and 4=very often for a total range of 0-96. The higher the overall score, the greater the probability the patient is at risk for displaying aberrant behaviors consistent with drug use.

An overall score of 18 or higher is considered positive for predicting aberrant drug related behavior, therefore the reported risk categories are

  • <18 and
  • <=18. Results indicate timeframe followed by risk cat
End of Open-label Titration Period. Weeks 4 and 24 of the Open-label Treatment Period
Addiction Behavior Checklist (ABC) Total Scores During Both the Open-Label Titration and Open-Label Treatment Periods by Participant Status
Ramy czasowe: Baseline for new participants was Day 1 of open-label titration; rollover participants baseline was in study 3079. End of Open-label Titration: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 40, 44, 48, 52 and last visit up to week 52
The ABC was a clinician rated scale that consisted of a brief (21 item) questionnaire designed to track behaviors characteristic of addiction related to prescription opioid medications in chronic pain populations. Items were focused on observable behaviors noted both during and between clinic visits. Each affirmative response was counted as 1 point, and points were added to calculate the total score. All but 1 of the 21 items (the provider's impression) was used in calculating the total score, consequently resulting in scores ranging from 0 to 20 (0=no addiction-related behaviors seen and higher scores indicating an increasing number of addition-related behaviors seen). Participants with a total score of 3 or greater were classified as exhibiting inappropriate opioid use during the study.
Baseline for new participants was Day 1 of open-label titration; rollover participants baseline was in study 3079. End of Open-label Titration: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 40, 44, 48, 52 and last visit up to week 52
Current Opioid Misuse Measure (COMM) Scores During Both the Open-Label Titration and Open-Label Treatment Periods by Participant Status
Ramy czasowe: Baseline for new participants was Day 1 of open-label titration; rollover participants baseline was in study 3079. End of Open-label Titration Period. Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 40, 44, 48, 52 and last visit up to week 52
The COMM was a clinician-rated scale developed as a brief self-report measure of current aberrant drug-related behavior for patients with chronic pain who were already on long-term opioid therapy. A total score was calculated as the sum of the 17 questions. The total score ranged from 0 to 68. A score of 0 indicates no aberrant drug-related behaviors were seen. Patients with a total score of 9 or greater were classified as exhibiting aberrant drug-related behavior.
Baseline for new participants was Day 1 of open-label titration; rollover participants baseline was in study 3079. End of Open-label Titration Period. Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 40, 44, 48, 52 and last visit up to week 52

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 października 2010

Zakończenie podstawowe (Rzeczywisty)

1 września 2012

Ukończenie studiów (Rzeczywisty)

1 września 2012

Daty rejestracji na studia

Pierwszy przesłany

15 października 2010

Pierwszy przesłany, który spełnia kryteria kontroli jakości

18 października 2010

Pierwszy wysłany (Oszacować)

19 października 2010

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

5 czerwca 2017

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

2 maja 2017

Ostatnia weryfikacja

1 maja 2017

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • C33237/3080

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Hydrocodone ER

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in France

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

3
Subskrybuj